Pro-Life Advocates Increase Pressure on FDA to Conduct Abortion Pill Review: FDA Head Responds

Pro-life leaders increased pressure on the FDA in relation to its review of the abortion pill mifepristone following a report suggesting that FDA Commissioner Dr. Marty Makary told officials to delay the review until after the midterm elections. Makary has denied the allegations.

HHS Provides New Update on Review of Abortion Pill Dangers

The U.S. Department of Health and Human Services (HHS) last week sent a letter to nearly two dozen state attorneys general detailing their active review of the dangerous abortion pill mifepristone.

‘Serious Risks to Women’: Over 20 Attorneys General Call for Regulation of Abortion Pill

‘[I]n the event the FDA is unable to reinstate the 2011 safety protocols for mifepristone, the FDA should consider withdrawing mifepristone from the market until it completes its review and can decide on a course of action based on objective safety and efficacy criteria,’ the attorneys general wrote.